EP Patent

EP2386294A3 — Unitary pharmaceutical dosage form comprising Tenofovir DF

Assigned to Gilead Sciences Inc · Expires 2012-01-25 · 14y expired

What this patent protects

In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenovofir DF (and, optionally, emtricitabine) and component 2 comprising efavire…

USPTO Abstract

In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenovofir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation. In another embodiment a composition comprising tenovofir DF and a surfactant is claimed.

Drugs covered by this patent

Patent Metadata

Patent number
EP2386294A3
Jurisdiction
EP
Classification
—
Expires
2012-01-25
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.